Cancer rash drug trial halted early – little known

NCT ID NCT04697069

Terminated Symptom relief Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This small, early-stage trial tested a drug called imsidolimab for treating acne-like skin rashes that can occur in cancer patients taking certain targeted therapies. Only 4 people were enrolled before the study was stopped. Because of the very small size and early termination, we cannot draw any reliable conclusions about whether the drug works or is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Imsidolimab (ANB019), a humanized monoclonal antibody
What this could lead to: If it worked, this could point toward a treatment for the painful skin rash that some cancer patients get from their medications.
What could go wrong: The trial was terminated early with only 4 participants, so we have very little data. It is unclear if the drug is effective or safe for this use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACNEIFORM ERUPTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acneiform dermatitis Acneiform Eruptions cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACNEIFORM ERUPTIONS

Contacts and locations

Locations

Site 101

St Louis, Missouri, 63110, United States
Site 102

Tampa, Florida, 33620, United States
Site 103

Houston, Texas, 77030, United States
Site 105

Columbus, Ohio, 43215, United States
Site 106

Boston, Massachusetts, 02215, United States
Site 201

Szczecin, 70-784, Poland
Site 203

Poznan, 60-569, Poland
Site 204

Gliwice, 44-102, Poland
Site 301

Olomouc, 779 00, Czechia
Site 302

New Town, Praha 2, 128 00, Czechia
Site 303

Brno, 656-91, Czechia
Site 304

Plzen-Bory, 305 99, Czechia
Site 401

Tbilisi, 0186, Georgia
Site 402

Tbilisi, 0144, Georgia
Site 403

Tbilisi, 0160, Georgia
Site 404

Batumi, 6000, Georgia
Site 405

Tbilisi, 0160, Georgia
Site 601

Riga, 1038, Latvia

More trials for these conditions

Other studies related to the condition(s) this trial covers.